Kerry O Cleveland

Dr. Kerry O Cleveland


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2016 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
RSR. Andrew Seaton
R. Andrew Seaton
AGArmando Gonzalez-Ruiz
Armando Gonzalez-Ruiz
KCKerry O Cleveland
Kerry O Cleveland
KCKimberly A. Couch
Kimberly A. Couch
RPRashidkhan Pathan
Rashidkhan Pathan
KHKamal Hamed
Kamal Hamed
Pooled data from two large registries, Cubicin® Outcomes Registry and Experience (CORE; USA) and European Cubicin® Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions. Patients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Gram-positive infections were included. Clinical success was defined as an outcome of ‘cured’ or ‘improved’. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment. In 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1–103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of high-dose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively. The real-world data showed that daptomycin was effective and safe in the treatment of various Gram-positive infections, including those caused by resistant pathogens, across wide geographical regions.

1 June 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
AHAthena Hobbs
Athena Hobbs
MGMichael S. Gelfand
Michael S. Gelfand
KCKerry O Cleveland
Kerry O Cleveland
KSKimberly Saddler
Kimberly Saddler
MSMiguel A. Sierra-Hoffman
Miguel A. Sierra-Hoffman
Eravacycline is a novel, fully-synthetic tetracycline approved by the FDA for treatment of complicated intra-abdominal infections in August 2018. This study sought to characterise early clinical experience with this novel antibiotic. Eravacycline utilisation for 66 patients was retrospectively evaluated. Eravacycline was used as monotherapy in 62.1% of cases. Mean duration of therapy was 13.1 ± 9.9 days. The majority (68.2%) of treatment was for off-label indications, including 34.8% for pulmonary and 28.8% for skin/soft tissue infections. A number of difficult-to-treat organisms were encountered: 50% of identified Gram-negative pathogens were resistant to carbapenems in vitro; and 48% of identified Gram-positive pathogens were resistant to vancomycin in vitro. The patient population had a high illness acuity, with 42.4% requiring ICU admission, 59.1% having ≥2 co-morbidities and 33.3% having ≥3 co-morbidities. Nevertheless, 95.5% experienced clinical improvement, with 86.4% achieving full infection resolution following eravacycline. Three patients who did not experience clinical improvement had an intra-abdominal source of infection without adequate source control. The remaining six who did not experience full infection resolution died from unrelated non-infectious causes during hospital admission. Adverse events were uncommon (4.5%), limited to nausea/vomiting, and not leading to eravacycline discontinuation. Although two patients had a history of Clostridioides difficile infection (CDI), no patients developed CDI while receiving eravacycline. These results illustrate the potential versatility of eravacycline with a broad activity spectrum, good safety and tolerability profile, flexibility for use in patients with renal injury or antibiotic allergies, and positive clinical outcomes in this real-world cohort.

10 August 2011 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
JTJennifer D. Twilla
Jennifer D. Twilla
MGMichael S. Gelfand
Michael S. Gelfand
KCKerry O Cleveland
Kerry O Cleveland
JUJustin B. Usery
Justin B. Usery

1 July 2014 in Infectious Diseases in Clinical Practice
Verified
Journal Article
Closed access
GRGopikishan Rangaraj
Gopikishan Rangaraj
KCKerry O Cleveland
Kerry O Cleveland
MGMikhail S. Gelfand
Mikhail S. Gelfand
Background Vertebral osteomyelitis is caused predominantly by Staphylococcus aureus, which is increasingly methicillin resistant. Our objective was to compare outcomes after use of vancomycin and daptomycin for treatment of vertebral osteomyelitis. Methods We conducted a retrospective chart review of all patients who received a diagnosis of vertebral osteomyelitis over a 6-year period at a tertiary care hospital in Memphis, Tennessee. Results Sixty-one patients were identified who received either vancomycin (n = 30) or daptomycin (n = 31) for vertebral osteomyelitis and had a follow-up period of at least 12 months. The mean duration of antibiotic therapy was 41 days in the vancomycin group and 45 days in the daptomycin group. Methicillin-resistant Staphylococcus aureus was identified in 81% of the vancomycin-treated patients and in 86% of the daptomycin-treated patients. Cure was significantly more likely to be obtained in the patients receiving daptomycin (97%) than in the patients treated with vancomycin (70%) (P = 0.0057). Conclusions When the mean duration of parenteral vancomycin or daptomycin approximates 6 weeks, cure rates for vertebral osteomyelitis equal or exceed 70%. The use of daptomycin resulted in a significantly higher rate of cure compared with that of vancomycin.

16 August 2011 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
SKSamuel Travis King
Samuel Travis King
JUJustin B. Usery
Justin B. Usery
KHKatherine Holloway
Katherine Holloway
LKLaura Koeth
Laura Koeth
KCKerry O Cleveland
Kerry O Cleveland
MGMichael S. Gelfand
Michael S. Gelfand
Enterobacteriaceae (except Proteus, Providencia and Morganella) with reduced susceptibility (,23 mm inhibition zone diameter or MIC .1 mg/L) to any of the carbapenems (ertapenem, imipenem or meropenem) will be tested for the carbapenemase phenotype by the combined disc method (with EDTA or boronic acid). 5 All strains with a positive phenotype will be sent to a reference laboratory for molecular testing. Hence, implementation of the new CLSI criteria would not simplify the laboratory testing and reporting procedure in our locality. Although susceptibility of Proteus spp., Providencia spp. and M. morganii to imipenem is recognized to be lowered and could be caused by mechanisms other than carbapenemase production, 1 the extent of the effect that applying the new interpretive criteria would have on clinical isolates has not been previously described. Here, we showed that susceptibility categorization for this group of organisms could change by up to 61.4%. Laboratories that choose to implement the new criteria should clearly inform infection control personnel so that there will not be any misunderstanding of outbreak occurrence. In conclusion, this study showed that applying the new CLSI criteria to interpret carbapenem susceptibility in Enterobacteriaceae would drastically change the susceptibility rates for some isolate groups. Furthermore, the FDA-approved breakpoints have not been changed. This explains why many clinical laboratories continue to use the old breakpoints and perform phenotypic testing for carbapenemase production. 3,6 Our findings emphasize the need to obtain more clinical outcome data.

5 May 2020 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
JRJoseph Reilly
Joseph Reilly
MJMicah A. Jacobs
Micah A. Jacobs
BFBruce Friedman
Bruce Friedman
KCKerry O Cleveland
Kerry O Cleveland
DLDavid A. Lombardi
David A. Lombardi
BCBibiana Castaneda-Ruiz
Bibiana Castaneda-Ruiz
Background Bacteremia and endocarditis caused by Staphylococcus aureus (S. aureus), particularly methicillin-resistant S. aureus (MRSA), are challenging to treat and are associated with high morbidity and mortality. Telavancin is a lipoglycopeptide antibacterial active against susceptible Gram-positive pathogens, including MRSA. Objective This registry study assessed the real-world use and clinical outcomes of telavancin in patients with bacteremia or endocarditis enrolled in the Telavancin Observation Use Registry (TOUR™). Methods The subset of patients enrolled in TOUR who were diagnosed with endocarditis and/or bacteremia with a known or unknown primary source (N = 151) were analyzed. Data including demographics, infection type, baseline pathogens, prior or concomitant antimicrobial therapy, dosing regimen, clinical response, treatment-emergent adverse events (TEAEs) of interest, and mortality were collected by retrospective medical chart review. Results Telavancin was primarily used as a second-line or greater therapy (n = 132, 87.4%). MRSA was present in 87 (57.6%) patients. Median telavancin dose was 740.6 mg (interquartile range (IQR) 206.0 mg) and median duration of therapy was 9.0 days (IQR 24.0 days). Of the 132/151 (87.4%) patients with an available assessment at the end of telavancin therapy, a positive clinical response was achieved in 98/132 (74.2%), while 14/132 (10.6%) failed therapy and 20/132 (15.2%) had an indeterminant outcome. TEAEs occurred in 24 (15.9%) patients. The most frequent TEAE was renal failure (n = 12, 7.9%); seven of these patients were receiving concomitant nephrotoxic medications. There was no change in creatinine clearance for 67/89 (75.3%) patients with values recorded at the beginning and the end of telavancin therapy. Conclusions In real-world clinical practice, overall positive clinical outcomes are observed in patients with bacteremia or endocarditis treated with telavancin, including in those patients infected with MRSA or another S. aureus pathogen. Telavancin may be an alternative treatment option for these patients. Trial Registration This trial was registered with clinicaltrials.gov (NCT02288234) on 11 November 2014.